|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
3
|
|
pubmed:dateCreated |
2007-12-17
|
|
pubmed:abstractText |
7-Hydroxystaurosporine (UCN-01) is a protein kinase inhibitor that inhibits several serine-threonine kinases including PKC and PDK1. Due to the preclinical synergistic effects seen with topoisomerase I inhibitors and non-overlapping toxicity, UCN-01 and irinotecan were combined in a dose-finding study designed to determine the maximum tolerated dose (MTD), toxicity profile, and pharmacokinetics (PK) of UCN-01 and irinotecan.
|
|
pubmed:grant |
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Mar
|
|
pubmed:issn |
0344-5704
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
61
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
423-33
|
|
pubmed:dateRevised |
2010-11-18
|
|
pubmed:meshHeading |
pubmed-meshheading:17429623-Adult,
pubmed-meshheading:17429623-Aged,
pubmed-meshheading:17429623-Antineoplastic Agents, Phytogenic,
pubmed-meshheading:17429623-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:17429623-Area Under Curve,
pubmed-meshheading:17429623-Camptothecin,
pubmed-meshheading:17429623-Enzyme Inhibitors,
pubmed-meshheading:17429623-Female,
pubmed-meshheading:17429623-Follow-Up Studies,
pubmed-meshheading:17429623-Humans,
pubmed-meshheading:17429623-Male,
pubmed-meshheading:17429623-Maximum Tolerated Dose,
pubmed-meshheading:17429623-Middle Aged,
pubmed-meshheading:17429623-Neoplasms,
pubmed-meshheading:17429623-Staurosporine,
pubmed-meshheading:17429623-Topoisomerase I Inhibitors
|
|
pubmed:year |
2008
|
|
pubmed:articleTitle |
Phase I and pharmacokinetic study of UCN-01 in combination with irinotecan in patients with solid tumors.
|
|
pubmed:affiliation |
The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Cancer Research Building I, Baltimore, MD, USA.
|
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't,
Clinical Trial, Phase I,
Research Support, N.I.H., Extramural
|
